CEO's Covid-19 Michael Castagna
Jun 4, 2020 10:00:51 GMT -5
via mobile
sportsrancho, yash, and 1 more like this
Post by itellthefuture777 on Jun 4, 2020 10:00:51 GMT -5
www.pharmexec.com/pharmaceutical-ceo-leadership-during-pandemic
Regeneron has been on the front-lines of COVID-19 therapeutics development using its VelociSuite technologies to develop a novel cocktail of fully human antibodies that are specifically targeted at the SARS-CoV-2 virus. It jumped into gear to address COVID-19, said CEO Leonard S. Schleifer, MD, PhD, in the early part of January, identifying the most potent and effective virus-neutralizing antibodies and scaling them up using Regeneron technologies, with the expectation of entering clinical trials in June.
At the other end of the spectrum, is Michael Castagna, CEO of MannKind, whose COVID-19 “a-ha” moment was around manufacturing and the company’s dry powder capabilities. He asked: “Is there an opportunity for us to take someone else’s therapy and replicate that into our inhaled platform and scale-up that up?”
baytownsun.com/coronavirus/article_c702ff4d-8567-5b13-ad86-dab871660801.html
Regeneron has been on the front-lines of COVID-19 therapeutics development using its VelociSuite technologies to develop a novel cocktail of fully human antibodies that are specifically targeted at the SARS-CoV-2 virus. It jumped into gear to address COVID-19, said CEO Leonard S. Schleifer, MD, PhD, in the early part of January, identifying the most potent and effective virus-neutralizing antibodies and scaling them up using Regeneron technologies, with the expectation of entering clinical trials in June.
At the other end of the spectrum, is Michael Castagna, CEO of MannKind, whose COVID-19 “a-ha” moment was around manufacturing and the company’s dry powder capabilities. He asked: “Is there an opportunity for us to take someone else’s therapy and replicate that into our inhaled platform and scale-up that up?”
baytownsun.com/coronavirus/article_c702ff4d-8567-5b13-ad86-dab871660801.html